RNAC logo

CARTESIAN THERAPEUTICS INC

RNACNASDAQ
πŸ† #3516 by market capEarnings Mar 8 Β· PostUS Equity
β€”β€”
Quote unavailable
πŸ””
Track RNAC
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$187M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-20.7%
Declining
πŸ“ŠGross Margin
β€”
πŸ’΅FCF Margin
422.1%
Strong
βš–οΈP/S Ratio
104.3x
Expensive
Otter Score
β€”
Insufficient data
No chart data available for RNAC.

Trading Snapshot

Day Range
β€”
52-Week Range
$5.60 – $11.00
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
30.3M
Next Earnings
2027-03-08

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
104.3x
EPS (TTM)
$-5.87
Dividend Yield
β€”
Dilution (1yr)
+0.3%
RNAC logo

CARTESIAN THERAPEUTICS INC

RNAC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3Mβ–Ό βˆ’92.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$87Mβ–² +97.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$79Mβ–² +142.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
26.0Mβ–² +0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$112Mβ–Ό βˆ’$86M YoY
StockOtter Β· stockotter.space

About CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

Zacks Investment ResearchΒ·6d ago

Bears are Losing Control Over Cartesian Therapeutics, Inc. (RNAC), Here's Why It's a 'Buy' Now

Cartesian Therapeutics, Inc. (RNAC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a tr

Zacks Investment ResearchΒ·12d ago

Wall Street Analysts See a 379.63% Upside in Cartesian Therapeutics, Inc. (RNAC): Can the Stock Really Move This High?

The consensus price target hints at a 379.6% upside potential for Cartesian Therapeutics, Inc. (RNAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat

GlobeNewsWireΒ·17d ago

Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027Β  Retreatment data for Descartes-08 in MG s

GlobeNewsWireΒ·19d ago

Cartesian Therapeutics Announces New Employment Inducement Grant

FREDERICK, Md., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the β€œCompany”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced

Seeking AlphaΒ·24d ago

Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement

Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gra

Defense WorldΒ·Oct 12

Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison

Syndax Pharmaceuticals (NASDAQ: SNDX - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two co